Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial
The topline results showed that Amelus and BF-RhodoLED lamp therapy met primary and secondary endpoints in the Phase III trial.
01 November 2024
01 November 2024
The topline results showed that Amelus and BF-RhodoLED lamp therapy met primary and secondary endpoints in the Phase III trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.